PX1 Research supplies analytical-grade Survodutide for in vitro and preclinical laboratory research. Every lot is manufactured in the USA, independently tested via RP-HPLC and mass spectrometry, and accompanied by a public certificate of analysis.
PX1 Research supplies analytical-grade Survodutide for in vitro and preclinical laboratory research. Every lot is manufactured in the USA, independently tested via RP-HPLC and mass spectrometry, and accompanied by a public certificate of analysis.
Qualified institutional researchers seeking a verified survodutide peptide for sale require strict analytical verification, lot-to-lot consistency, and documented purity. Survodutide (BI 456906) is a novel dual glucagon receptor (GCGR) and glucagon-like peptide-1 receptor (GLP-1R) agonist developed for non-clinical metabolic research. PX1 Research provides high-purity lyophilized Survodutide synthesize in USA-based facilities, formatted strictly for laboratory assay and animal model investigation.
When purchasing compounds for cellular assays or animal models, raw purity directly impacts experimental reproducibility. Impurities such as truncated peptide sequences, residual TFA (trifluoroacetic acid), or high endotoxin levels can confound downstream receptor binding affinities and metabolic assays. PX1 Research addresses these standard laboratory risks by subjecting every batch of research peptides to rigorous identity and purity testing prior to distribution.
Survodutide is an acylated peptide engineered to exhibit target activation at both the GLP-1 receptor and the glucagon receptor. Structurally, it incorporates a C18 fatty diacid moiety attached to a specific lysine residue via a linker. This acylation promotes reversible binding to plasma albumin, significantly extending its biological half-life in preclinical models compared to native peptide hormones.
In contrast to selective mono-agonists, the dual engagement of GLP-1R and GCGR triggers complementary intracellular signaling cascades. GLP-1R activation stimulates cyclic AMP (cAMP) production in pancreatic beta cells and central neuronal pathways modulating satiety. Concurrently, GCGR activation in hepatic tissue engages cAMP/protein kinase A (PKA) signaling, promoting glycogenolysis and mitochondrial fatty acid oxidation. In vitro radioligand binding assays indicate that Survodutide maintains balanced potent activation across both human and rodent receptor isoforms.
In animal models of metabolic dysfunction and diet-induced obesity (DIO), preclinical studies demonstrate that dual GCGR/GLP-1R agonism produces synergistic reductions in body mass and liver fat deposition. While GLP-1 receptor activation reduces food intake through central pathways, glucagon receptor stimulation increases resting energy expenditure by uncoupling hepatic oxidative phosphorylation and elevating energy dissipation.
Rodent research models treated with dual agonists exhibit substantial reductions in hepatic steatosis, lower circulating triglycerides, and enhanced insulin sensitivity. In vitro assays using primary hepatocytes demonstrate elevated beta-oxidation gene expression (such as CPT1a and PPAR-alpha) upon exposure to Survodutide. Researchers utilizing glp-1 receptor agonists in liver disease models frequently select dual glucagon/GLP-1 co-agonists to study direct hepatocyte lipid clearance mechanisms alongside appetite modulation.
Evaluating multi-receptor therapeutics requires comparing binding profiles and target engagement spectrums across different peptide classes. When designing comparative metabolic protocols, investigators frequently evaluate mono-agonists, dual agonists, and tri-agonists side-by-side in established animal models.
Selective GLP-1 receptor agonists like semaglutide primarily modulate glucose-dependent insulin secretion and central satiety mechanisms without directly increasing basal metabolic rate via hepatic pathways. Dual GLP-1R/GIP agonists like tirzepatide combine incretin pathways to optimize beta-cell responsiveness and adipocyte lipid storage. In contrast, Survodutide incorporates direct glucagon receptor activation to stimulate hepatic energy expenditure. Emerging multi-target agents like retatrutide expand this spectrum further by targeting GLP-1R, GIPR, and GCGR simultaneously. The dual GCGR/GLP-1R selectivity of Survodutide offers a distinct biochemical probe for isolating the specific synergistic effects of glucagon and GLP-1 signaling without GIP receptor cross-talk.
To ensure high experimental integrity, PX1 Research subjects all lot fabrications to comprehensive analytical testing performed by independent ISO 17025 accredited testing facilities. Every vial of survodutide peptide for sale is accompanied by a downloadable Certificate of Analysis (COA) detailing clear, lot-specific metrics.
Purity is verified using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC), ensuring a minimum purity standard of >= 98.0%. Exact molecular mass and sequence integrity are verified via Electrospray Ionization Mass Spectrometry (ESI-MS), confirming the absence of wrong-sequence side products or incomplete coupling fragments. Crucially for cell culture and in vivo administration, chromogenic LAL assays ensure bacterial endotoxin content remains strictly below 0.5 EU/mg.
Survodutide is supplied as a sterile, lyophilized cake or powder designed for reconstitution in analytical laboratories. For optimal stability and minimal peptide aggregation, reconstitution should follow precise lab protocols using suitable aqueous buffers depending on downstream application context.
For short-term working solutions in in vitro assays, sterile physiological saline or phosphate-buffered saline (PBS, pH 7.4) may be utilized. When preparing stock solutions for extended multi-dose animal studies, reconstituting with bacteriostatic water containing 0.9% benzyl alcohol prevents microbial proliferation during repeated vial access. Laboratory personnel should avoid vigorous vortexing; gentle swirling or passive dissolution at room temperature prevents physical shear stress and potential peptide aggregation. Detailed solvent interaction guidelines are available in our peptide reconstitution calculator guide.
Proper temperature control is essential to maintain structural stability and prevent chemical degradation, such as deamidation or oxidation of sensitive amino acid residues within the peptide chain. Unopened, lyophilized vials of Survodutide should be stored long-term at -20°C or -80°C in a desiccated environment protected from light.
Once reconstituted, peptide solutions should be aliquoted into single-use polypropylene microtubes to eliminate freeze-thaw cycles, which degrade secondary structure. Reconstituted aliquots stored at 4°C are stable for up to 14 days, whereas aliquots frozen at -20°C remain stable for up to 90 days. Investigators seeking bulk quantities for long-term study protocols can review logistics via our wholesale lab account portal.
Procuring reliable peptides for academic or corporate research requires rigorous vendor vetting. Sourcing non-verified compounds from unaccredited overseas suppliers introduces risk regarding batch inconsistency, incorrect salt formulations, and unaccounted endotoxin contamination that invalidates research data.
PX1 Research maintains complete chain-of-custody transparency. All products are manufactured in GMP-compliant USA facilities, tested per-lot by third-party laboratories, and shipped directly from domestic distribution hubs in California and Arizona. Orders placed Monday through Friday ship same-day, ensuring fast, reliable delivery for active laboratory schedules. Explore our comprehensive publication index on the PX1 research portal for technical whitepapers and compound profiles.
What is the primary mechanism of action of Survodutide in research models?
Survodutide (BI 456906) acts as a dual agonist at both the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR). Preclinical studies indicate it simultaneously activates central satiety pathways via GLP-1R and hepatic fatty acid oxidation via GCGR.
What analytical testing is provided with PX1 Research Survodutide?
Every lot of Survodutide includes a third-party Certificate of Analysis (COA) verifying purity (>= 98% via RP-HPLC), exact molecular weight (via ESI-MS mass spectrometry), and endotoxin levels (< 0.5 EU/mg via chromogenic LAL assay).
How should lyophilized Survodutide be stored upon delivery?
Lyophilized Survodutide should be stored at -20°C or -80°C in a desiccated, dark environment. Under these conditions, the unhydrated peptide remains stable for up to 24 months.
What solvents are recommended for reconstituting Survodutide for laboratory assays?
For standard laboratory research, Survodutide can be reconstituted using sterile bacteriostatic water (for multi-use stock solutions) or sterile 0.9% sodium chloride / PBS (for immediate in vitro or animal administration).
How does Survodutide differ from Tirzepatide in preclinical studies?
While Tirzepatide targets GLP-1R and GIPR (glucose-dependent insulinotropic polypeptide receptor), Survodutide targets GLP-1R and GCGR (glucagon receptor). Survodutide specifically engages hepatic glucagon pathways to directly stimulate energy expenditure alongside GLP-1 signaling.
Can Survodutide be purchased for human clinical use or personal administration?
No. Survodutide supplied by PX1 Research is strictly designated for laboratory research use only (RUO). It is not for human or veterinary use, medical treatment, diagnosis, or therapeutic applications.
Where is PX1 Research Survodutide manufactured and shipped from?
All PX1 Research compounds are manufactured in USA-based facilities adhering to strict quality controls and shipped directly from fulfillment centers in California and Arizona with same-day shipping on orders placed Monday through Friday.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.